NDLI: Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.

Please wait, while we are loading the content...

Sexual satisfaction, sexual compatibility, and relationship adjustment in couples: the role of sexual behaviors, orgasm, and men's discernment of women's intercourse orgasm.

The reduction corporoplasty: the answer to the improbable urologic question 'can you make my penis smaller?'.

Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats.

Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy.

Ginsenoside Rg3 improves erectile function in streptozotocin-induced diabetic rats.

The influence of sexual orientation and sexual role on male grooming-related injuries and infections.

Sexual dysfunction among reproductive-aged Chinese married women in Hong Kong: prevalence, risk factors, and associated consequences.

Newly diagnosed erectile dysfunction and risk of depression: a population-based 5-year follow-up study in Taiwan.

Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome.

Nitrergic function is lost but endothelial function is preserved in the corpus cavernosum and penile resistance arteries of men after radical prostatectomy.

Alterations in microRNA expression in a murine model of diet-induced vasculogenic erectile dysfunction.

Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism.

Nature and origin of 'squirting' in female sexuality.

Asexuality: an extreme variant of sexual desire disorder?

Why is impaired sexual function distressing to women? The primacy of pleasure in female sexual dysfunction.

Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors.

Low testosterone has a similar prevalence among men with sexual dysfunction due to either Peyronie's disease or erectile dysfunction and does not correlate with Peyronie's disease severity.

The impact of disrupted childhood attachment on the presentation of psychogenic erectile dysfunction: an exploratory study.

Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria.

Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.

Diminished functional connectivity on the road to child sexual abuse in pedophilia.

The relationship between self-estimated intravaginal ejaculatory latency time and International Prostate Symptom Score in middle-aged men complaining of ejaculating prematurely in China.

Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature.

Postorgasmic illness syndrome (POIS) in a Chinese man: no proof for IgE-mediated allergy to semen.

Vibrators and other sex toys are commonly recommended to patients, but does size matter? Dimensions of commonly sold products.

Predictors of improvement in sexual function of women with urinary incontinence after treatment with pelvic floor exercises: a secondary analysis.

Commentary on Kärgel and colleagues' study: diminished functional connectivity on the road to child sexual abuse in pedophilia.

Appreciation of diversity and nomenclature within clinical practice.

Sexual health care for people with physical disabilities.

Year: 2015 Volume: 12 Issue: Supplementary 3

Year: 2015 Volume: 12 Issue: 2

Year: 2015 Volume: 12 Issue: Supplementary 2

Year: 2015 Volume: 12 Issue: 1

Year: 2015 Volume: 12 Issue: Supplementary 1

Year: 2014 Volume: 11

Year: 2013 Volume: 10

Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Burns, Patrick R. Rosen, Raymond C. Dunn, Marian Baygani, Simin K. Perelman, Michael A.
Description	Country affiliation: United States Author Affiliation: Burns PR ( Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.)
Abstract	INTRODUCTION: Treatment satisfaction of men receiving phosphodiesterase 5 inhibitors (PDE5) for erectile dysfunction (ED) and their partners is essential to successful long-term therapy. AIM: This study aims to assess treatment satisfaction, in men with a partial response to on-demand (PRN) PDE5 and their female partners, following tadalafil 5 mg once daily or placebo. METHODS: The study was randomized, double-blind, parallel, and placebo-controlled in men primarily with mild to moderate ED. Treatment satisfaction was assessed following a 4-week maximum dose PRN lead-in, 4-week nondrug washout, and treatment through 12 weeks. Men were ≥18 years old with ED for ≥3 months and International Index of Erectile Function Erectile Function score of ≥17 and <26 at screening and <26 following PRN lead-in. MAIN OUTCOME MEASURES: Treatment satisfaction was assessed using the Treatment Satisfaction Scale (TSS) for patients and partners. TSS domain scores range from 0 to 100, with higher values indicating greater satisfaction. Statistical comparisons were made using analysis of covariance. RESULTS: Treatment satisfaction was significantly greater with tadalafil once daily vs. placebo across all TSS domains for both patients and their partners (all P < 0.001). For patients, mean scores for the TSS domains Confidence to Complete Sexual Activity and Satisfaction with Orgasm ranged from 53.7 to 57.8 after the PRN lead-in and 26.7 to 31.9 following the nondrug washout. Following randomized treatment, scores for tadalafil and placebo were 55.4 and 32.6, respectively, for Confidence to Complete Sexual Activity and 57.5 and 37.9, respectively, for Satisfaction with Orgasm. Results were comparable for other TSS domains and between men and their partners. CONCLUSIONS: Treatment satisfaction was comparable for tadalafil 5 mg once daily and PRN PDE5 for both patients and female partners, suggesting that tadalafil once daily is a viable therapy option for men with ED who had a partial response to PRN PDE5 therapy.
File Format	HTM / HTML
ISSN	17436095
Issue Number	3
Volume Number	12
e-ISSN	17436109
Journal	The Journal of Sexual Medicine
Language	English
Publisher	Elsevier
Publisher Date	2015-03-01
Publisher Place	Netherlands
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Urology Discipline Sexology Carbolines Administration & Dosage Erectile Dysfunction Drug Therapy Prevention & Control Patient Satisfaction Statistics & Numerical Data Penile Erection Drug Effects Phosphodiesterase 5 Inhibitors Sexual Partners Psychology Adult Dose-response Relationship, Drug Double-blind Method Drug Administration Schedule Physiopathology Female Humans Male Middle Aged Tadalafil Treatment Outcome Journal Article Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Urology Endocrinology Reproductive Medicine Psychiatry and Mental Health Obstetrics and Gynecology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.

Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.

A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.

Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction.

Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.

A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.

Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.

Similar Documents

Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.

Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.

A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.

Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction.

Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.

A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.

Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.